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Introduction
Colorectal cancers (CRCs) confined to the submucosa (pT1) 
are found in approximately 5%-13% of overall CRC patients. 
[1,2] Although curative resection anticipates good clinical 
outcomes in T1 CRC, non-surgical treatment is of interest due 
to reduced additional burden. Accurate prediction of lymph 
node metastasis (LNM) after endoscopic resection or local 
excision is essential for deciding if additional curative resec-
tion is needed. Japanese Society for Cancer of the Colon and 
Rectum (JSCCR) guidelines (“Japanese criteria”) recommends 
an additional surgical resection if one or more of the following 
is applicable: (1) positive vertical resection margin; (2) depth 
of submucosa invasion ≥ 1,000 μm; (3) lymphovascular inva-
sion (LVI) positive; (4) poorly differentiated adenocarcinoma, 
signet ring cell carcinoma, or mucinous carcinoma; or (5) 
grade 2/3 budding at the site of deepest invasion [3]. This cri-
terion is based mainly on pathologic features of the obtained 
specimens. In fact, most of the patients who underwent such 
additional surgeries harbor no metastatic lymph nodes [4-6], 
resulting in overtreatment. The probability of LNM is known 
to increase with more risk factors [7], but these additional 
risks do not seem to be taken into account because the current 
guidelines only make all-or-nothing decisions based on each 
included variable. Given the lack of a reliable tool that can 
predict LNM, additional biomarkers have been investigated 
to raise the predictability using different approaches [8,9].
Tumor-infiltrating lymphocytes (TILs) mediate local host 
anti-tumor immunity of human malignancies and are known 
to be important prognostic factors in various cancers [10,11]. 
TILs are composed of various regulatory subtypes. CD8+ T 
lymphocytes are critical effectors of anti-tumor immunity 
and CD4+ T lymphocytes help induce, maintain, and memo-
rize CD8+ T cells [12]. A subset of T cells, called regulatory 
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Purpose  The role of tumor-infiltrating lymphocytes (TILs) in predicting lymph node metastasis (LNM) in patients with T1 colorectal 
cancer (CRC) remains unclear. Furthermore, clinical utility of a machine learning–based approach has not been widely studied. 
Materials and Methods  Immunohistochemistry for TILs against CD3, CD8, and forkhead box P3 in both center and invasive margin 
of the tumor were performed using surgically resected T1 CRC slides. Three hundred and sixteen patients were enrolled and cat-
egorized into training (n=221) and validation (n=95) sets via random sampling. Using clinicopathologic variables including TILs, the 
least absolute shrinkage and selection operator (LASSO) regression model was applied for variable selection and predictive signature 
building in the training set. The predictive accuracy of our model and the Japanese criteria were compared using area under the 
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decision curve analysis (DCA) in the validation set.
Results  LNM was detected in 29 (13.1%) and 12 (12.6%) patients in training and validation sets, respectively. Nine variables were 
selected and used to generate the LASSO model. Its performance was similar in training and validation sets (AUROC, 0.795 vs. 0.765; 
p=0.747). In the validation set, the LASSO model showed better outcomes in predicting LNM than Japanese criteria, as measured by 
AUROC (0.765 vs. 0.518, p=0.003) and NRI (0.447, p=0.039)/IDI (0.121, p=0.034). DCA showed positive net benefits in using our 
model. 
Conclusion  Our LASSO model incorporating histopathologic parameters and TILs showed superior performance compared to con-
ventional Japanese criteria in predicting LNM in patients with T1 CRC.
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T lymphocytes, inhibit anti-tumor immune reaction and are 
considered a key factor in immune escape in cancer patients. 
The transcription factor forkhead box P3 (FOXP3) functions 
as a master regulator of the development and function of 
regulatory T cells and is an important developmental factor 
for CD4+CD25+ T regulatory cells that distinguishes ‘‘regula-
tory cells’’ from conventional ‘‘helper cells’’ among the CD4+ 
helper T cells [13,14]. Previous studies have demonstrated 
that immunoscores (defined as summation of specific num-
ber imposed according to the densities of CD3+ or CD8+ posi-
tive cells in tumor center [TC] and invasive margin [IM]) are 
better at estimating patient’s prognosis compared to the TNM 
stage system in colon and rectal cancers, respectively [15]. 
Nevertheless, the respective prognostic role of spatial distri-
bution of CD3+ and CD8+ in stage II and stage III CRC showed 
different results [16,17]. Moreover, the role of TILs in predict-
ing LNM in T1 CRC has not been investigated sufficiently. 
Machine learning–based algorithms have been widely used 
in clinical decision making [18]. Of them, the least absolute 
shrinkage and selection operator (LASSO) is one of the most 
commonly used algorithms and its clinical efficacy has been 
demonstrated previously [17,19]. Such situations could yield 
many insights for the adoption of machine learning algo-
rithms in predicting LNM in T1 CRC. 
The aim of the present study was to investigate the predic-
tive value of immunohistochemistry (IHC) results of TILs 
in addition to routinely reported pathologic parameters. In 
addition, we hypothesized that a machine learning–based 
algorithm that incorporated TILs and conventional histo-
pathologic parameters could be used to improve the predic-
tive accuracy of detecting LNM in T1 CRC patients undergo-
ing curative resection. 
Materials and Methods
 
1. Patients and samples
Patients were identified from a prospectively collected 
database of CRC resections in a tertiary referral center. This 
retrospective, single center based study initially considered 
a total of 381 patients who had undergone potentially cura-
tive resection of pathologic T1 CRC between April 2004 and 
December 2011. In case of CRCs treated with endoscopic pro-
cedures such as endoscopic mucosal resection or endoscopic 
submucosal dissection, surgeons usually recommended 
additional curative surgical resection with lymph node dis-
section to the patients when invasion to submucosa or deep-
er was suspected, resection margin was either vertical or 
lateral involvement was detected, LVI was noted, or poorly 
differentiated or mucinous/signet ring cell carcinoma were 
reported. In this study, we included surgically resected speci-
mens only, which allowed us to evaluate the correct patho-
logic LNM status. 
The inclusion criteria for this study was the availability of 
formalin-fixed, paraffin-embedded tissue. Exclusion criteria 
were as follows: those who underwent neoadjuvant therapy, 
such as preoperative chemoradiotherapy for rectal cancer 
or neoadjuvant chemotherapy for colon cancer; those who 
underwent emergency operations; those who had a history 
of hereditary nonpolyposis CRC, ulcerative colitis or Crohn’s 
disease; those who was diagnosed as stage IV; and patients 
with missing data i.e., total retrieved lymph node numbers. 
Finally, 316 patients met the inclusion criteria and consti-
tute the study cohort. This study conforms to the TRIPOD 
(Transparent Reporting of a Multivariable Prediction Model 
for Individual Prognosis or Diagnosis) statement for studies 
developing a prediction model. 
2. Pathologic evaluation
For this retrospective study, the examinations of patholog-
ic features, including depth of gross morphology, histologic 
grade, depth of submucosa invasion, LVI, tumor budding, 
presence of background adenoma (BGA), and immuno-
chemical examinations were conducted by a single experi-
enced pathologist (Y.J.C.) who did not know the patient’s 
clinical outcomes or LNM status.
Level 2 of Haggitt’s classification for pedunculated type 
and muscularis mucosae in other non-pedunculated type, 
such as sessile and superficial cancers, were used as baseline. 
The vertical distance from baseline to the deepest invasive 
lesion was used as the depth of invasion in our study [4]. 
Tumors were classified histologically as: well, moderately, 
and poorly differentiated adenocarcinomas or as mucinous 
or signet ring cell type, based on the most predominant 
histologic feature [8]. Tumor budding is a cancer cell clus-
ter composed of fewer than five cancer or undifferentiated 
cells, isolated from large cancer portions without forming 
a unique structure [20]. After selecting the area where bud-
ding foci was most intense, the number of budding foci were 
counted using a magnification of ×200 in hematoxylin and 
eosin stained (H&E) slides. Tumor budding was defined as 
high in case of presence of more than five tumor budding, 
otherwise it was defined as low [21]. LVI was evaluated 
using H&E slides. 
3. IHC and evaluation of IHC results using image analysis 
software
Representative sections of primary tumors were pro-
cessed for additional immunohistochemical staining with 
antibodies against mismatch repair (MMR) status (MLH1 
[1:400, clone ES05, Leica Biosystems, Newcastle upon Tyne, 
UK] and MSH2 [1:800, clone G219-1129, Cell Marque, Rock-
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lin, CA]) and TILs such as CD3 (1:200, clone F7.2.38, Dako, 
Glostrup, Denmark), CD8 (1:100, clone C8/144B, Dako), 
and FOXP3 (1:150, clone 236A/E7, Abcam, Cambridge, UK) 
using a BOND-MAX automatic stainer (Leica Biosystems, 
Melbourne, Australia) with Bond Polymer Refine Detection 
(Leica Biosystems, Newcastle upon Tyne, UK) kit. 
To evaluate the MMR status, adjacent normal colon tissue 
served as an internal control for positive staining and a nega-
tive control staining was carried out without the primary 
antibody. Expression was reported as either MMR proficient 
(tumor cell nuclear expression with positive immune cell 
expression) or MMR deficient (tumor nuclear expression 
absent with normal immune cell expression). 
An automated imaging software program (Image Pro Plus 
ver. 7.0, Media Cybernetics, Rockville, MD) was used to eval-
uate the percentage of each TILs subtype among the detected 
cells. The density of TILs was expressed by measuring the 
area occupied by mononuclear cells over the stromal area 
captured by NIS-Element F (ver. 4.30, Nikon, Tokyo, Japan) 
under ×400 magnification. Immunoreactivity was measured 
at two points: in the center of the tumor (TC) and in the IM 
(S1 Fig.). Spatial location of TC and IM was selected by the 
pathologist. The mean percentage of the three areas occupied 
by TILs in TC and IM per section was reported as the density 
of TILs.
4. Development of LASSO-derived prediction model in the 
training set
A total of 316 patients were allocated to the training and 
validation sets using computer-generated random sampling 
at a fixed ratio; 70% of the patients were assigned to the train-
ing set and the remaining 30% were assigned to the valida-
tion set. 
Using clinicopathologic variables, including TILs informa-
tion dichotomized into high and low subgroups according 
to the spatial distributions, LASSO regression was used to 
generate the predictive model in the training set. LASSO 
regression is known to be able to remove unimportant vari-
ables via the regression coefficients penalizing the size of the 
parameters. Applying the LASSO regression method, fea-
ture selection and predictive signature building was done. 
LASSO regression shrinks the coefficient estimates toward 
zero, with the degree of shrinkage dependent on an addi-
tional parameter, λ. To determine the optimal values for λ, 
a 10-time cross-validation was used, and we chose λ via the 
minimum criteria. The LASSO model was designed to pre-
dict the presence of LNM in patients with T1 CRC and is the 
linear predictor of the binary model built on the training set 
with selected variables via LASSO algorithm.
5. Validation of LASSO model using area under the receiv-
er operating characteristic, net reclassification improve-
ment, integrated discrimination improvement, and deci-
sion curve analysis in the validation set
The performance of the LASSO model, in comparison to 
Japanese criteria, was measured via area under the receiver 
operating characteristic (AUROC) analysis, net reclassifica-
tion improvement (NRI), integrated discrimination improve-
ment (IDI) calculation, and decision curve analysis (DCA) 
in the validation set. NRI quantifies the net proportion of 
patients with and without event of interest who are reclassi-
fied as higher and lower risk, respectively. 
6. Statistical analysis
The clinicopathologic characteristics were analyzed using 
a variance test where appropriate. The chi-square test or 
Fisher exact test was used for comparison of categorical vari-
ables. Continuous variables were analyzed via Student t test 
or Mann-Whitney U test. The cutoff values for all immuno-
histochemical markers were determined at the maximum of 
Youden’s index and the maximum of accuracy. A univari-
able analysis was performed to calculate the odds ratio of 
the single variables in the logistic regression (LR) model after 
entering one of the variables under investigation. Univari-
able analysis denoted the association between LNM and the 
parameter through a 1:1 matching. 
A two-sided p-value less than 0.05 was considered statis-
tically significant. All statistical analyses were performed 
using SPSS software ver. 23.0 (IBM Corp., Armonk, NY) and 
R ver. 3.5.1 (R-project, Institute for Statistics and Mathemat-
ics, Vienna, Austria). 
Results
1. Patient characteristics
Three hundred and sixteen patients were included in our 
analysis. Our initial cohort was categorized into 221 patients 
in the training set and the remaining 95 patients in the vali-
dation set. LNM was detected in 29 (13.1%) and 12 (12.6%) 
patients after a curative resection in the training and valida-
tion sets, respectively.
Table 1 demonstrates the characteristics of the training and 
the validation set. No significant differences were observed 
with respect to sex, age, tumor location, depth of invasion, 
LVI, tumor budding, BGA, LNM, and the rate of MMR 
between the two groups. In contrast, proportion of more than 
five of carcinoembryonic antigen (CEA); proportion of G2, 
G3, and mucinous type; and proportion of pedunculated 
morphology were significantly higher in the validation set 
(all p < 0.05). 
2. Distribution of TILs and defining cut-off value of TILs 
in the training set
Distribution of TILs according to LNM based on the ana-
tomical location are illustrated in S2 Fig. We found no sig-
nificant difference in the mean numbers between the LNM 
status. Receiver operating characteristic curve analysis to 
predict LNM based on each TILs subtype’s densities and 
AUROC values are shown in S3 Fig. and S4 Table. Area 
under the curve (AUC) values are 0.55, 0.50, 0.50, 0.59, 0.52, 
and 0.53 in CD3_invasive margin (CD3_IM), CD3_tumor 
center (CD3_TC), CD8_invasive margin (CD8_IM), CD8_ 
tumor center (CD8_TC), FOXP3_invasive margin (FOXP3_
IM), and FOXP3_tumor center (FOXP3_TC), respectively. 
We calculated the cut-off value of each TILs subtype using 
Table 1.  Comparison of clinicopathological characteristics between the training and validation set
 Training set (n=221) Validation set (n=95) p-value
Sex
    Male 123 (55.7) 59 (62.1) 0.347
    Female 98 (44.3) 36 (37.9) 
Age (yr)   
    < 70 177 (80.1) 77 (81.1) 0.966
    ≥ 70 44 (19.9) 18 (18.9) 
Preoperative CEA (ng/mL)   
    < 5.0 208 (94.1) 73 (76.8) < 0.001
    ≥ 5.0 13 (5.9) 22 (23.2) 
Tumor location   
    Colon 129 (58.4) 60 (63.2) 0.502
    Rectum 92 (41.6) 35 (36.8) 
Retrieved lymph node numbers  12 (7-17) 14 (12-21) < 0.001
Depth of invasion (μm)   
    < 1,000 20 (9.0) 6 (6.3) 0.557
    ≥ 1,000 201 (91.0) 89 (93.7) 
Histologic gradea)   
    G1 93 (42.1) 28 (29.5) 0.047
    G2, G3, etc. 128 (57.9) 67 (70.5) 
LVI   
    Present 27 (12.2) 14 (14.7) 0.668
    Absent 194 (87.8) 81 (85.3) 
Gross morphology   
    Pedunculated 17 (7.7) 16 (16.8) 0.025
    Flat and sessile 204 (92.3) 79 (83.2) 
Tumor buddingb)   
    Low grade 88 (39.8) 38 (40.0) > 0.99
    High grade 133 (60.2) 57 (60.0) 
Background adenoma   
    Present 196 (88.7) 84 (88.4) > 0.99
    Absent 25 (11.3) 11 (11.6) 
LNM   
    Negative 192 (86.9) 83 (87.4) > 0.99
    Positive 29 (13.1) 12 (12.6) 
MMR   
    MMR-deficient 14 (6.3) 8 (8.4) 0.669
    MMR-proficient 207 (93.7) 87 (91.6) 
Values are presented as number (%) or median (IQR). CEA, carcinoembryonic antigen; IQR, interquartile range; LNM, lymph node  
metastasis; LVI, lymphovascular invasion; MMR: mismatch repair. a)Histologic grade: G1, well differentiated; G2, moderately differenti ated; 
G3, poorly differentiated, b)Tumor budding grade was as follows: grade 1, 0-4/grade 2, 5-9/grade 3, 10 or more. Grade 1 was defined as low 
grade and grade 2/3 as high grade.
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Table 2.  Univariable analysis for predicting lymph node metastasis in the training set (n=221)
 LN positive, n (%)
                            Univariable analysis
  OR (95% CI) p-value 
Sex 
    Female 14/98 (14.3) Reference 
    Male 15/123 (12.2) 0.833 (0.37-1.83) 0.647
Age (yr)   
    < 70 24/177 (13.6) Reference 
    ≥ 70 5/33 (11.4) 0.817 (0.26-2.12) 0.699
Preoperative CEA (ng/mL)   
    < 5.0 27/208 (13.0) Reference 
    ≥ 5.0 2/13 (15.4) 1.218 (0.18-4.86) 0.803
Tumor location   
    Colon 14/129 (10.9) Reference 
    Rectum 15/92 (16.3) 1.6 (0.72-3.53) 0.239
Depth of invasion (μm)   
    < 1,000 3/20 (15.0) Reference 
    ≥ 1,000 26/201 (12.9) 0.841 (0.25-3.78) 0.794
Histologic gradea)   
    G1 7/93 (7.5) Reference 
    G2, G3, etc. 22/128 (17.2) 2.549 (1.08-6.70) 0.040
LVI   
    Absent 20/194 (10.3) Reference 
    Present 9/27 (33.3) 4.35 (1.67-10.84) 0.001
Gross morphology   
    Pedunculated 2/17 (11.8) Reference 
    Flat and sessile 27/204 (13.2) 1.144 (0.29-7.51) 0.863
Tumor buddingb)   
    Low grade 10/133 (7.5) Reference 
    High grade 19/88 (21.6) 3.387 (1.52-7.97) 0.003
Background adenoma   
    Present  22/196 (11.2) Reference 
    Absent 7/25 (20.0) 3.075 (1.09-7.96) 0.024
MMR   
    MMR-deficient 1/14 (7.1) Reference 
    MMR-proficient 28/207 (13.5) 2.033 (0.38-37.65) 0.502
CD3_IM   
    Low (< 11.3) 10/55 (18.2) Reference 
    High (≥ 11.3) 19/166 (11.4) 0.581 (0.25-1.38) 0.203
CD3_TC   
    Low (< 9.2) 2/39 (5.1) Reference 
    High (≥ 9.2) 27/182 (14.8) 3.222 (0.90-20.53) 0.121
CD8_IM   
    Low (< 28.2) 29/199 (14.6) Reference 
    High (≥ 28.2) 0/27 (0) 0 (NA-1.68e+26) 0.990
CD8_TC   
    Low (< 18.5) 24/133 (18.0) Reference 
    High (≥ 18.5) 5/88 (5.7) 0.273 (0.08-0.69) 0.011
FOXP3_IM   
    Low (< 15.1) 16/99 (16.2) Reference 
    High (≥ 15.1) 13/122 (10.7) 0.618 (0.27-1.35) 0.230
(Continued to the next page)
Youden’s index to be 11.3, 9.2, 28.2, 18.5, 15.1, and 20.3 in 
CD3_IM, CD3_TC, CD8_IM, CD8_TC, FOXP3_IM, and 
FOXP3_TC, respectively (S4 Table). Each TILs subtype was 
categorized as high or low according to these cutoff values. 
3. Univariable analysis using clinicopathologic parameters 
and TILs for predicting LNM in the training set
There was no difference in incidence of LNM due to sex, 
age, CEA level, tumor location, depth of invasion, and gross 
morphology (pedunculated versus others). Mean depth of 
invasion did not differ according to LNM (2,947 μm in lymph 
node [LN]–positive group vs. 2,550 μm in LN-negative group, 
p=0.099). Among clinicopathologic parameters, histologic 
grade (grade 1 vs. grade 2, grade 3 and etc., p=0.040), LVI 
(positive vs. negative, p=0.001), tumor budding (presence vs. 
absence, p=0.003), and BGA (absence vs. presence, p=0.024) 
were associated with LNM in the training set. With respect 
to TILs, CD8 densities in TC dichotomized as 18.5 were iden-
tified as a significant parameter for predicting LNM in the 
training set (p=0.011) (Table 2).
4. Generating LASSO model to predict LNM in the train-
ing set
The binomial deviance curve was plotted versus log (λ), 
where λ is a tuning hyperparameter. Solid vertical lines rep-
resent binomial deviance±standard error (SE). The dotted 
vertical lines are drawn at optimal values by using the mini-
mum criteria and 1-SE criteria. An optimal λ value was selec-
ted for the LASSO model by using 10-fold cross-validation 
via minimum criteria (Fig. 1A). A value of λ=0.02469015 with 
log (λ)=–3.701351 was chosen. A coefficient profile plot was 
produced against the log (λ) sequence (Fig. 1B). Training the 
optimized model with the training set resulted in nine non-
zero coefficients for histology grade (grade 1 vs. others), LVI 
(absence vs. presence), tumor budding (absence vs. presence), 
BGA (presence vs. absence), CD3_IM (high vs. low), CD3_TC 
(high vs. low), CD8_IM (high vs. low), CD8_TC (high vs. low), 
and FOXP3_TC (high vs. low) with coefficients 0.28665580, 
Fig. 1.  Selection of significant parameters in clinicopathologic variables in the training set and definition of linear predictor. (A) Ten time 
cross-validation for tuning parameter selection in the LASSO model. (B) LASSO coefficient profiles. The LASSO was used for regression of 
high dimensional predictors. The method uses an L1 penalty to shrink some regression coefficients to exactly zero. The binomial deviance 
curve was plotted versus log (λ), where λ is the tuning parameter (A). LASSO coefficient profiles of clinicopathologic variables (B). LASSO, 
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Table 2.  Continued
 LN positive, n (%)
                            Univariable analysis
  OR (95% CI) p-value 
FOXP3_TC   
    Low (< 20.3) 23/157 (14.6) Reference 
    High (≥ 20.3) 6/64 (9.4) 0.602 (0.21-1.47) 0.290
CEA, carcinoembryonic antigen; CI, confidence interval; IM, invasive margin; LN, lymph node; LVI, lymphovascular invasion; MMR, 
mismatch repair; NA, not available; OR, odds ratio; TC, tumor center. a)Histologic grade: G1, well differentiated; G2, moderately differenti-
ated; G3, poorly differentiated, b)Tumor budding grade was as follows: grade 1, 0-4/grade 2, 5-9/grade 3, 10 or more. Grade 1 was defined 
as low grade and grade 2/3 as high grade.
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0.84002838, 0.60610111, 0.33894896, –0.07225639, 0.34769731, 
–0.35012378, –0.66414982, and –0.03525056, respectively. 
The linear predictor was defined as (–2.51312270)+histo- 
logy grade (grade 1 vs. others)×(0.28665580)+LVI (absence 
vs. presence)×(0.84002838)+tumor budding (absence vs. pre- 
sence)×(0.60610111)+BGA (presence vs. absence)×(0.3389-
4896)+CD3_IM (high vs. low)×(–0.07225639)+CD3_TC (high 
vs. low)×(0.34769731)+CD8_IM (high vs. low)×(‒0.35012378)+ 
CD8_TC (high vs. low)×(–0.66414982)+FOXP3_TC (high vs. 
low)×(–0.03525056).
5. Performance of the LASSO model in the validation set
AUROC comparison of the LASSO model in the training 
and validation sets showed similar results. (AUROC, 0.795 
vs. 0.765; p=0.747) (Fig. 2). In Japanese criteria, patients with 
either one of the following results were classified as positive 
Fig. 2.  Comparison of AUROC between LASSO model in the 
training and validation sets and Japanese criteria in the valida-
tion set. AUC, area under the curve; AUROC, area under the  
receiver operating characteristic; CI, confidence interval; LAS-
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Table 3.  NRI and IDI in the training set and the validation set
                            Training set (n=221)                    Validation set (n=95)
 Japanese criteria vs. LASSO model p-value Japanese criteria vs. LASSO model p-value 
NRI (95% CI)a) 0.722 (0.402-1.041) < 0.001 0.447 (0.041-0.854) 0.039
IDI (95% CI) 0.187 (0.100-0.274) < 0.001 0.121 (0.008-0.234) 0.034 
CI, confidence interval; LASSO, least absolute shrinkage and selection operator; NRI, net reclassification improvement. a)Cutoff of “0, 0.1, 
0.2, 1” was used in this analysis.
Fig. 3.  Decision curve analysis of Japanese criteria and LASSO model in the training (A) and validation (B) set. The y-axis measures the net 
benefit. The green line represents the LASSO model. The red line represents the Japanese criteria. The gray line represents the assumption 
that all patients underwent surgeries. The black line represents the assumption that patients underwent no surgeries. The net benefit was 
calculated by subtracting the proportion of all patients who are false positive from the proportion who are true positive, weighting by the 
relative harm of forgoing treatment compared with the negative consequences of an unnecessary treatment. The decision curve showed 
that if the threshold probability of a patient or doctor is >10%, using the LASSO model in the current study to predict LNM adds more 
benefit than the treat-all-patients scheme or the treat-none scheme. For example, if the personal threshold probability of a patient is 20% 
(i.e., the patient would opt for surgery if his/her probability of LNM was > 20%), then the net benefit is 0.35 when using the LASSO model 
to make the decision of whether to undergo surgery, with added benefit than the treat-all scheme or the treat-none scheme. This decision 
curve analysis showed that the net benefit was comparable on the basis of the Japanese criteria and the treat-all or treat-none strategies. 
















































for the surgery group (coded as 1) and other patients were 
denoted as negative for the surgery group (coded as 0): posi-
tive vertical resection margin, depth of submucosa invasion 
≥ 1,000 μm, LVI positive, poorly differentiated adenocarci-
noma, signet ring cell carcinoma, or mucinous carcinoma or 
grade 2/3 budding at the site of deepest invasion. 
In the validation set, AUROC demonstrated better predic-
tive accuracy of LASSO model compared to Japanese criteria 
(0.765 in the LASSO model vs. 0.518 in the Japanese criteria, 
p=0.003) (Fig. 2). In addition, the LASSO model showed sig-
nificantly improved prediction for LNM compared to Japa-
nese criteria, as measured by NRI (0.447, p=0.039) and IDI 
(0.121, p=0.034) (Table 3). DCA showed positive net benefit 
in using LASSO model in the training set and validation set, 
respectively (Fig. 3). Sensitivity, specificity, positive predic-
tive value, and negative predictive value using the LASSO 
model at each cut-off point in overall set are illustrated in S5 
Table. 
6. Clinical significance of immunoscore-like score in pre-
dicting LNM in T1 CRC
Immunoscore-like score was calculated based on the rec-
ommendation [15]. In our cohort, there was no difference 
in immunoscore-like score between the LN positive and the 
negative group (p=0.630) (S6 Fig.).
Discussion
Previous studies investigating predictors of LNM in T1 
CRC mainly focused on histopathologic parameters [4,22]. 
Although we expect the combination of pathologic risk fac-
tors could help in discriminating the risk of LNM in most 
patients with T1 CRC, more than 80% of the patients who 
were candidates for additional surgery were node-negative 
in final pathologic examinations. This study demonstrated 
that a machine learning–based algorithm that incorporated 
clinicopathologic parameters and TILs showed high predic-
tive accuracy of LNM in T1 CRC and had superior discrimi-
natory performance when compared with the conventional 
Japanese criteria.
Although prognostic value of the inflammatory cell reac-
tion on survival in CRC has been thoroughly studied, the 
role of lymphocytic infiltration on LNM in early CRC has 
not been studied as extensively. A previous study consider-
ing peritumoral lymphocytic infiltration (PLI) as one of the 
candidates to predict LNM did not reveal any difference 
of PLI rate between the node-positive and node-negative 
groups. [20] Although statistically insignificant, the rate of 
PLI was conspicuous—at 8.3% in the node-positive group 
and 22.6% in the node-negative group (p=0.1). Considering 
the relatively low number of enrolled patients (n=111), the 
lack of association might be due to a type-II error [20]. Com-
pared to the H&E slide–based evaluation of PLI in the previ-
ous study, we evaluated the role of IHC-stained TILs at dif-
ferent anatomical subsites, such as IM and TC. Univariable 
analysis demonstrated that lower densities of CD8+ T cells 
in TC were significantly correlated with higher rate of LNM 
in T1 CRC. In the equation that formed the linear predictor 
of LASSO model, the absolute value of CD8_TC (0.66414982) 
was larger than that of other IHC values. This result indi-
cates that CD8_TC acted as one of the most obvious factors 
in predicting LNM, which was predictable from the results of 
univariable analysis.
A recent meta-analysis reported that the clinical signifi-
cance of various TILs in CRC showed definite differences 
according to anatomical subsites [23]. High densities of CD3+ 
T cells indicated poor disease-free survival (DFS) in the 
invasive margin, whereas high densities of CD8+ T cells 
were a favorable prognosticator with respect to DFS in 
tumor center. Furthermore, several studies demonstrated 
that the significance of specific TILs according to spatial 
distribution might be different depending on the stage. One 
study revealed that both CD3+ T cells in both TC and IM are 
favorable prognosticators in stage III colon cancer, whereas 
another study observed the same trends only in stage II 
colon cancer but not in stage III colon cancer [16,17]. As 
far as we know, the clinical significance of spatial distribu-
tion of TILs as a predictor of LNM in T1 CRC has not been 
investigated sufficiently. When applying LR-based univaria-
ble or multivariable analysis, only CD8_TC would be left as an 
independent factor. In contrast, using LASSO model, we can 
estimate the relative role of each spatial TILs subtype using 
the coefficients imposed on respective variables. Along with 
CD8_TC, CD3_TC, and CD8_IM are thought to have a cer-
tain role in predicting LNM, although the direction of CD3_
TC and CD8_IM would be different. Considering the differ-
ent roles of each TILs subtype depending on the anatomical 
subsites or stages in non-metastatic CRC patients, it appears 
that our LASSO model is more reflective of the complex 
interactions of each TILs subtype. Further research is requi-
red to confirm our hypothesis.
Several recent studies have introduced machine learning 
algorithms for predicting LNM in T1 CRC [18,24,25]. It was 
reported that an artificial intelligence model using support 
vector machine (SVM) showed better discrimination than the 
LR-based model (AUC; 0.821 in SVM vs. 0.789 in LR, p=not 
stated) among 100 validation sets out of 690 T1 CRC patients 
[18]. The other study developed a random forest classifier–
based prediction model using cytokeratin immunostaining 
images of resected whole slide images and reported similar 
predictive ability (AUC, p=0.1) and fewer false-negative cas-
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es compared to the LR-based clinical model [24]. However, 
one should bear in mind that the LR-based clinical models 
that were used to compare with the aforementioned machine 
learning algorithms (SVM and random forest classifier) were 
not the same as the Japanese criteria–based decision model. 
The risk assessment LR-based model generated in the prior 
two studies constructed prediction probabilities by combin-
ing each conventional histopathologic risk factor, whereas 
the Japanese criteria classified patients solely into “surgery” 
or “no surgery” subgroups without considering the imposed 
risk of each clinicopathologic variable. It is in this context 
that we developed a LASSO model and compared it with the 
Japanese criteria used in current clinical practice. The LAS-
SO-based prediction model is a classifier that can accumulate 
relative risks of meaningful variables and maximize its pre-
dictive power. This fundamental characteristic might be one 
possible reason for the better diagnostic accuracy of the LAS-
SO model. In a similar way, a recent Dutch T1 CRC work-
ing group demonstrated that a LASSO-derived prediction 
model (AUC, 0.83; 95% confidence interval [CI], 0.76 to 0.90) 
showed better AUC value than the conventional prediction 
models suggested by American Society for Gastrointestinal 
Endoscopy/European Society of Gastrointestinal Endoscopy 
(AUC, 0.67; 95% CI, 0.60 to 0.74; p=0.002) and JSCCR guide-
lines (AUC, 0.64; 95% CI, 0.58 to 0.70; p < 0.001), respectively, 
in 708 T1 pedunculated colorectal carcinoma [25].
Previously, the depth of invasion of T1 CRC was classified 
as SM1 (submucosa 1), SM2, and SM3, respectively [26]. The 
rate of LNM according to this definition was reported as 0%-
3% in SM1, 8%-10% in SM2, and 23%-25% in SM3 [27,28], and 
SM3 was regarded as a strong indicator for an additional sur-
gery. To clarify the depth of invasion using SM categories, the 
whole submucosa layer should be evaluated, which is not 
always possible after endoscopic treatment. In a large retro-
spective study, it was recommended that a 1,000 μm depth of 
invasion could be used as a cut-off value for predicting LNM 
[4]. In our study, however, there was no difference of LNM 
rate according to depth of invasion dichotomized as 1,000 
μm and, therefore, depth of invasion was not selected as a 
parameter in the LASSO model. Although it is very difficult 
to explain why depth of invasion did not predict LNM in our 
cohort, there are several other studies that also reported no 
association between depth of invasion with LNM [8,22,29]. 
Selection bias might be one possible reason for this dissocia-
tion [29]. In addition, long-span retrospective studies under-
going histopathologic examinations by various pathologists 
inevitably showed some heterogeneities of dealing with 
pathologic slides. In our study, depth of invasion as well as 
other histopathologic parameters were re-evaluated for this 
study by one pathologist, which is a merit of this study. Large 
scale prospective studies are required to reveal the discrep-
ancy of the role of depth of invasion on LNM in T1 CRC. 
The main limitation of our study is that it was based on 
a single center, retrospective data collection. Our hospital is 
one of the largest referral centers in our nation, which skews 
cases toward more advanced stage patients. The accuracy of 
Japanese criteria measured by AUC in this study was around 
0.52, which is approximately the same probability as tossing 
a coin. Such a situation would be very embarrassing given its 
firm status as a predictive model. Although this might reflect 
the real situation, some unmeasurable biases, such as inclu-
sion of only patients who underwent surgeries, might have 
acted in reducing the overall performance. Nevertheless, it 
is impossible to identify the actual incidence of LNM among 
those patients who did not undergo surgeries, and such a sit-
uation would be the main dilemma in dealing with this issue. 
Also, IHC on paraffin sections might be semiquantitative 
although we applied image analyzer–based measurements. 
Artificial intelligence–guided whole slide image analysis has 
been actively adopted in medicine [17]. It would be an inter-
esting issue that computer-aided detection could minimize 
the subjectivity of measuring TILs using pathologic manual 
estimation or image analyzer–based measurements [30]. 
Despite the internal validation, a larger prospective external 
validation is required before the LASSO model can be used 
as a clinical decision maker. It is expected that endoscopic 
resection will be performed more frequently as the incidence 
of early CRC increases. Therefore, it is considered to be very 
important clinically whether the predictive power can be 
increased through such TILs measurement and machine 
learning adoption in the specimen after endoscopic proce-
dure. Our study has a limitation in that it cannot provide a 
direct answer to such a point because it is not a study using 
a tissue from endoscopic procedure. However, if the center 
and IM of the tumor can be identified pathologically even in 
specimens using endoscopic resection, the model developed 
by us can be used when the density of each location can be 
measured after IHC. Additional research is needed to con-
firm the possibility in practical application.
In conclusion, we developed a LASSO-based prediction 
model for predicting LNM in patients with T1 CRC, and it 
outperformed the current Japanese guidelines. This finding 
suggests that machine learning can potentially improve the 
accuracy of prediction, thereby minimizing unnecessary sur-
gical resections. As the rate of CRCs detected early is grow-
ing, incidence of endoscopic treatments for early stage CRC 
may also be increasing. Evaluation of TILs after endoscopic 
treatments and application of a new prediction model might 
be beneficial in deciding for a subsequent radical surgery in 
T1 CRC. 
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